MDT

100.81

+0.69%↑

A

139.19

+2.17%↑

VEEV

224.79

+2.19%↑

HQY

85.18

+0.72%↑

NEOG

9.99

+5.83%↑

MDT

100.81

+0.69%↑

A

139.19

+2.17%↑

VEEV

224.79

+2.19%↑

HQY

85.18

+0.72%↑

NEOG

9.99

+5.83%↑

MDT

100.81

+0.69%↑

A

139.19

+2.17%↑

VEEV

224.79

+2.19%↑

HQY

85.18

+0.72%↑

NEOG

9.99

+5.83%↑

MDT

100.81

+0.69%↑

A

139.19

+2.17%↑

VEEV

224.79

+2.19%↑

HQY

85.18

+0.72%↑

NEOG

9.99

+5.83%↑

MDT

100.81

+0.69%↑

A

139.19

+2.17%↑

VEEV

224.79

+2.19%↑

HQY

85.18

+0.72%↑

NEOG

9.99

+5.83%↑

Search

Ligand Pharmaceuticals Inc

Open

SectorGezondheidszorg

197.55 0.12

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

194.95

Max

202.13

Belangrijke statistieken

By Trading Economics

Inkomsten

112M

117M

Verkoop

115M

K/W

Sectorgemiddelde

84.636

89.037

Winstmarge

101.569

Werknemers

68

EBITDA

87M

149M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+22.05% upside

Dividenden

By Dow Jones

Volgende Winsten

26 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-321M

3.8B

Vorige openingsprijs

197.43

Vorige sluitingsprijs

197.55

Nieuwssentiment

By Acuity

23%

77%

55 / 360 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 jan 2026, 23:49 UTC

Belangrijke Marktbewegers

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21 jan 2026, 21:12 UTC

Belangrijke Marktbewegers

Automaker Stocks Rise After Trump Calls Off European Tariffs

21 jan 2026, 21:00 UTC

Acquisities, Fusies, Overnames

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21 jan 2026, 20:29 UTC

Belangrijke Marktbewegers

Chip Makers Gain After Trump Calls Off European Tariffs

21 jan 2026, 20:04 UTC

Belangrijke Marktbewegers

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21 jan 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21 jan 2026, 23:34 UTC

Marktinformatie

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21 jan 2026, 22:39 UTC

Winsten

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21 jan 2026, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

21 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

21 jan 2026, 21:35 UTC

Acquisities, Fusies, Overnames

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21 jan 2026, 21:19 UTC

Winsten

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21 jan 2026, 20:45 UTC

Acquisities, Fusies, Overnames

Deutsche Borse Group to Acquire Allfunds for $6.19B

21 jan 2026, 20:36 UTC

Marktinformatie

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21 jan 2026, 20:31 UTC

Marktinformatie

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21 jan 2026, 20:27 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21 jan 2026, 20:27 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

21 jan 2026, 20:27 UTC

Marktinformatie

Was It a 'TACO' Event? -- Market Talk

21 jan 2026, 20:26 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21 jan 2026, 20:23 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21 jan 2026, 20:21 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21 jan 2026, 20:19 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse Group Agrees to Buy Allfunds

21 jan 2026, 20:08 UTC

Winsten

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21 jan 2026, 20:03 UTC

Marktinformatie

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21 jan 2026, 19:51 UTC

Marktinformatie

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21 jan 2026, 19:43 UTC

Marktinformatie

U.S. Ethanol Production Expected to Slip -- Market Talk

21 jan 2026, 19:31 UTC

Marktinformatie

Gold Settles at Fresh All-Time High -- Market Talk

21 jan 2026, 19:24 UTC

Winsten

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 jan 2026, 19:10 UTC

Marktinformatie

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21 jan 2026, 18:57 UTC

Marktinformatie

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Peer Vergelijking

Prijswijziging

Ligand Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

22.05% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 243.5 USD  22.05%

Hoogste 275 USD

Laagste 220 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ligand Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technische score

By Trading Central

102.5 / 109.24Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Very Strong Bearish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

55 / 360 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat